Zhejiang Medicine Co., Ltd. (SHA:600216)

Market Cap	11.26B -12.8%
Revenue (ttm)	8.82B -6.0%
Net Income	751.31M -48.5%
EPS	0.78 -49.3%
Shares Out	947.91M
PE Ratio	15.21
Forward PE	10.06
Dividend	0.28 (2.35%)
Ex-Dividend Date	Jul 21, 2025

Volume	9,860,311
Open	11.91
Previous Close	11.92
Day's Range	11.79 - 11.99
52-Week Range	11.80 - 18.58
Beta	0.32
Analysts	Buy
Price Target	17.60 (+48.15%)
Earnings Date	Aug 25, 2026

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin produc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 5,417
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2025, Zhejiang Medicine's revenue was 8.88 billion, a decrease of -5.28% compared to the previous year's 9.38 billion. Earnings were 873.38 million, a decrease of -24.74%.

Analyst Summary

According to 2 analysts, the average rating for 600216 stock is "Buy." The 12-month stock price target is ¥17.60, which is an increase of 48.15% from the latest price.

Price Target

¥17.60

(48.15% upside)

Analyst Consensus: Buy